Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | PRKACA | P17612 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.34 |
| ▸ | CDK8 | P49336 | 2/20 | 0.34 |
| ▸ | NEK2 | P51955 | 2/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953008 | 0.67 | — | — | |
| SCHEMBL334476 | 0.65 | KDM4E (0.55) | ABL1LCKFYNPRKACAKDR | |
| SCHEMBL21305165 | 0.58 | KIF11 (0.35) | ABL1LCKFYNPRKACAKDR | |
| SCHEMBL5491174 | 0.58 | — | — | |
| SCHEMBL4948871 | 0.57 | — | — | |
| SCHEMBL4956174 | 0.57 | — | — | |
| SCHEMBL4912618 | 0.56 | — | — | |
| SCHEMBL19327434 | 0.55 | AURKA (0.32) | ABL1LCKFYNPRKACAKDR | |
| SCHEMBL4955511 | 0.53 | — | — | |
| SCHEMBL4953997 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7341606-B2 | Medium and bicyclic fused 5-5-membered aza heteroaromatic derivative having ring junction nitrogen and N-hydroxy or N-amino group as developer and coupler; safe; kits | THE PROCTER & GAMBLE COMPANY (US) | 2008-03-11 | — | — | US | claimed |
| US-20070050923-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | WELLA OPERATIONS US, LLC | 2007-03-08 | — | — | US | claimed |
| US-7341606-B2 | Medium and bicyclic fused 5-5-membered aza heteroaromatic derivative having ring junction nitrogen and N-hydroxy or N-amino group as developer and coupler; safe; kits | THE PROCTER & GAMBLE COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1796615-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter & Gamble Company (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006026433-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070050923-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, NOX5, JUP | ABL1 3262/4885LCK 3509/4885FYN 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.